Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events

• Published in: Nature clinical practice cardiovascular medicine Vol. 6; no. 3; pp. 229 - 239
• Main Authors: Jaeger, Beate R, Richter, Yvonne, Nagel, Dorothea, Heigl, Franz, Vogt, Anja, Roeseler, Eberhard, Parhofer, Klaus, Ramlow, Wolfgang, Koch, Michael, Utermann, Gerd, Labarrere, Carlos A, Seidel, Dietrich
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 01.03.2009
• Subjects: Adult; Aged; Antilipemic agents; Blood Component Removal; Blood lipoproteins; Cohort Studies; Combined Modality Therapy; Coronary Artery Disease - drug therapy; Coronary Artery Disease - prevention & control; Coronary Artery Disease - therapy; Coronary heart disease; Dosage and administration; Female; Health aspects; Humans; Hypolipidemic Agents - therapeutic use; Lipoprotein(a) - blood; Lipoproteins; Longitudinal Studies; Male; Middle Aged; Prevention; Proteolipids; Risk factors; Treatment Outcome; Germany
• ISSN: 1743-4297; 1759-5002; 1743-4300; 1759-5010
• DOI: 10.1038/ncpcardio1456

We investigated in a longitudinal, multicenter, cohort study whether combined lipid apheresis and lipid-lowering medication can reduce extremely high levels of lipoprotein(a) (Lp[a]) and thus prevent major adverse coronary events (MACE) more efficaciously than lipid-lowering medication alone. Eligible patients had coronary artery disease and Lp(a) levels > or =2.14 micromol/l (95th percentile). All patients received lipid-lowering medications alone until maximally tolerated doses were no longer effective, followed by combined lipid apheresis and lipid-lowering medication. The rates of the primary outcome, MACE, were recorded for both periods. A total of 120 patients were included. The mean duration of lipid-lowering therapy alone was 5.6+/-5.8 years, and that of apheresis was 5.0+/-3.6 years. Median Lp(a) concentration was reduced from 4.00 micromol/l to 1.07 micromol/l with apheresis treatment (P<0.0001); the corresponding mean annual MACE rate per patient was 1.056 versus 0.144 (P<0.0001). Lowering of Lp(a) levels by apheresis was efficacious and safe, and we recommend this therapy for patients in whom maximally tolerated doses of medication alone have failed to control coronary artery disease-associated events.